Xynos Konstantinos sold $148K of REPL
Xynos Konstantinos (Chief Medical Officer) sold 11,447 shares of Replimune Group, Inc. (REPL) at $12.97 ($0.15M total) on 2026-08-10.
How this was made
The 30-second read
Why it matters
This provides a fresh datapoint on insider behavior (CMO selling 11,447 shares) but no new company fundamentals, guidance, or regulatory/clinical milestones.
Market read
Traders may monitor insider activity, but the disclosure alone is unlikely to drive a durable repricing without corroborating fundamental news.
What to watch
Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; the filing does not indicate intent to change strategy or company outlook.
Background
The article is a SEC Form 4 insider transaction disclosure for Replimune Group, Inc.
Ticker impact
Replimune Group disclosed an insider open-market sale by CMO Xynos Konstantinos of 11,447 shares at $12.97 on Aug 10.
Likely limited near-term impact; any reaction would be sentiment-driven rather than fundamentals.
Form 4 insider transactions are common and typically not predictive without accompanying company-specific news; the article provides sale size, price, and post-transaction holdings only.
Market effects
Minimal, as this is company-specific insider selling with no sector-wide catalyst.
None indicated.
None indicated.
Counterpoint
Absence of a 10b5-1 plan could be interpreted as less “pre-scheduled” selling, which some traders may read as near-term caution.
Key entities
- issuerReplimune Group, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderXynos Konstantinos
Chief Medical Officer who sold shares in an open-market transaction.
